Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Assets (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Current Assets for 16 consecutive years, with $332.6 million as the latest value for Q4 2025.

  • Quarterly Current Assets rose 11.61% to $332.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $332.6 million through Dec 2025, up 11.61% year-over-year, with the annual reading at $332.6 million for FY2025, 11.61% up from the prior year.
  • Current Assets for Q4 2025 was $332.6 million at Myriad Genetics, down from $344.8 million in the prior quarter.
  • The five-year high for Current Assets was $538.9 million in Q2 2021, with the low at $261.6 million in Q1 2023.
  • Average Current Assets over 5 years is $341.5 million, with a median of $305.8 million recorded in 2023.
  • The sharpest move saw Current Assets skyrocketed 62.47% in 2021, then plummeted 43.36% in 2022.
  • Over 5 years, Current Assets stood at $484.8 million in 2021, then tumbled by 43.36% to $274.6 million in 2022, then rose by 14.2% to $313.6 million in 2023, then dropped by 4.97% to $298.0 million in 2024, then increased by 11.61% to $332.6 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $332.6 million, $344.8 million, and $284.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.